Hims & Hers (HIMS 4.02%) announced today the launch of an early detection cancer test, bringing more value to its lab business. This is another product launch that isn't about pushing pills or slotting into the existing insurance ecosystem; it's fundamentally disruptive to the medical industry. In this video, I explain why this is the kind of product launch investors should want to see and why it will make the business much more valuable over the next decade.
*Stock prices used were end-of-day prices of Feb. 4, 2026. The video was published on Feb. 4, 2026.
